Skip to content

A retrospective study of icaritin in Chinese patients with non-surgically resectable stage IIa-IIIb hepatocellular carcinoma

A retrospective study of icaritin in Chinese patients with non-surgically resectable stage IIa-IIIb hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074565
Enrollment
Unknown
Registered
2023-08-09
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Case serise (Retrospective section):No

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 18 and 80; 2. Patients with histological/cytological confirmed hepatocellular carcinoma or cirrhosis meet the American Association for the Study of Hepatology (AASLD) clinical diagnostic criteria for hepatocellular carcinoma. The clinical diagnostic criteria refer to the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2022 Edition) 3. HCC patients eligible for China liver cancer staging (CNLC) Stage IIa-IIIb, which cannot be resectable, are not suitable for radical treatment. 4. According to the RECIST v1.1 standard, there must be at least one measurable lesion on the upper abdominal enhanced CT or MRI.

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating women; 2. other conditions that, in the judgment of the clinician, make the patient unsuitable for enrollment

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
Objective response rate;Overall survival;

Countries

China

Contacts

Public ContactGuoliang Shao

Zhejiang Cancer Hospital

shaogl@zjcc.org.cn+86 139 5818 3472

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026